Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 100 | $284.56 | $28,456.00 |
DisclosureSEC source: 0001209191-20-042492 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,692 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $284.56 (range $284.37 to $284.74). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 20:51 UTC |
Silva Paul MSVP & Controller
|
Exercise / conversionCommon Stock | 860 | $90.29 | $77,649.40 |
DisclosureSEC source: 0001209191-20-042492 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 20:16 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 260 | $293.90 | $76,414.00 |
DisclosureSEC source: 0001209191-20-042359 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,126 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $293.90 (range $293.43 to $294.39). Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 20:16 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 400 | $292.86 | $117,144.00 |
DisclosureSEC source: 0001209191-20-042359 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,386 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $292.86 (range $292.41 to $293.26). F3 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 20:16 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 40 | $291.19 | $11,647.60 |
DisclosureSEC source: 0001209191-20-042359 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,786 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionStock Option (Right to buy) · Derivative | 1,222 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-20-041969 · doc4.xml · derivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,561 Underlying: Common Stock · 1,222 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionStock Option (Right to buy) · Derivative | 1,564 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-20-041969 · doc4.xml · derivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,206 Underlying: Common Stock · 1,564 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 2,786 | $300.00 | $835,800.00 |
DisclosureSEC source: 0001209191-20-041969 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,179 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 1,222 | $155.57 | $190,106.54 |
DisclosureSEC source: 0001209191-20-041969 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:13 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 1,564 | $187.53 | $293,296.92 |
DisclosureSEC source: 0001209191-20-041969 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:15 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 200 | $291.34 | $58,268.00 |
DisclosureSEC source: 0001209191-20-040271 · doc4.xml · nonDerivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,261 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $291.34 (range $291.31 to $291.36). Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:15 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 2,534 | $290.51 | $736,152.34 |
DisclosureSEC source: 0001209191-20-040271 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,461 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $290.51 (range $290.12 to $290.87). Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:15 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 500 | $289.39 | $144,695.00 |
DisclosureSEC source: 0001209191-20-040271 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,995 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $289.39 (range $289.07 to $289.99). Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:15 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 1,318 | $287.91 | $379,465.38 |
DisclosureSEC source: 0001209191-20-040271 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,495 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $287.91 (range $287.75 to $288.16). Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:15 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 4,885 | $287.23 | $1,403,118.55 |
DisclosureSEC source: 0001209191-20-040271 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,813 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $287.23 (range $286.74 to $287.73). Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:15 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 8,321 | $286.13 | $2,380,887.73 |
DisclosureSEC source: 0001209191-20-040271 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,698 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $286.13 (range $285.71 to $286.66). Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:15 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 9,233 | $285.11 | $2,632,420.63 |
DisclosureSEC source: 0001209191-20-040271 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,019 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $285.11 (range $284.70 to $285.66). Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:15 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
SaleCommon Stock | 5,801 | $284.14 | $1,648,296.14 |
DisclosureSEC source: 0001209191-20-040271 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,252 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $284.14 (range $283.60 to $284.59). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:39 UTC |
MCKENZIE DIANADirector
|
GrantCommon Stock | 1,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034747 · doc4.xml · nonDerivative · entry 1 MCKENZIE DIANA · CIK 0001754648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,435 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 20:22 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 50 | $285.73 | $14,286.50 |
DisclosureSEC source: 0001209191-20-033993 · doc4.xml · nonDerivative · entry 7 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,695 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 20:22 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 50 | $284.62 | $14,231.00 |
DisclosureSEC source: 0001209191-20-033993 · doc4.xml · nonDerivative · entry 6 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,745 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 20:22 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 289 | $283.84 | $82,029.76 |
DisclosureSEC source: 0001209191-20-033993 · doc4.xml · nonDerivative · entry 5 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,795 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $283.84 (range $283.47 to $284.23). Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 20:22 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 313 | $282.86 | $88,535.18 |
DisclosureSEC source: 0001209191-20-033993 · doc4.xml · nonDerivative · entry 4 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,084 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F4 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $282.86 (range $282.36 to $283.31). Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 20:22 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 200 | $281.20 | $56,240.00 |
DisclosureSEC source: 0001209191-20-033993 · doc4.xml · nonDerivative · entry 3 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,397 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $281.20 (range $281.01 to $281.66). F4 · price: Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 02, 2020 Filed Jun 3, 2020 20:22 UTC |
Bhatia Sangeeta N.Director
|
SaleCommon Stock | 50 | $279.52 | $13,976.00 |
DisclosureSEC source: 0001209191-20-033993 · doc4.xml · nonDerivative · entry 2 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,597 F2 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:22 UTC |
Bhatia Sangeeta N.Director
|
GrantCommon Stock | 1,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-033993 · doc4.xml · nonDerivative · entry 1 Bhatia Sangeeta N. · CIK 0001643921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,647 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:24 UTC |
CARNEY LLOYDDirector
|
GrantCommon Stock | 1,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034002 · doc4.xml · nonDerivative · entry 1 CARNEY LLOYD · CIK 0001204424 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,559 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:26 UTC |
Garber Alan MDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,264 | $0.00 Strike: $286.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034012 · doc4.xml · derivative · entry 2 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,264 Underlying: Common Stock · 2,264 shares Expires 2030-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:26 UTC |
Garber Alan MDirector
|
GrantCommon Stock | 699 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034012 · doc4.xml · nonDerivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,890 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:29 UTC |
Kearney Terrence CDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,527 | $0.00 Strike: $286.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034027 · doc4.xml · derivative · entry 1 Kearney Terrence C · CIK 0001289098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,527 Underlying: Common Stock · 4,527 shares Expires 2030-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:31 UTC |
Lee YuchunDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,527 | $0.00 Strike: $286.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034038 · doc4.xml · derivative · entry 1 Lee Yuchun · CIK 0001334365 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,527 Underlying: Common Stock · 4,527 shares Expires 2030-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:35 UTC |
MCGLYNN MARGARET GDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,264 | $0.00 Strike: $286.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034048 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,264 Underlying: Common Stock · 2,264 shares Expires 2030-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:35 UTC |
MCGLYNN MARGARET GDirector
|
GrantCommon Stock | 699 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034048 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:36 UTC |
SACHS BRUCE IDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,527 | $0.00 Strike: $286.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034049 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,527 Underlying: Common Stock · 4,527 shares Expires 2030-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:38 UTC |
YOUNG WILLIAM DDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,527 | $0.00 Strike: $286.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034055 · doc4.xml · derivative · entry 1 YOUNG WILLIAM D · CIK 0001217420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,527 Underlying: Common Stock · 4,527 shares Expires 2030-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:14 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 311 | $282.74 | $87,932.14 |
DisclosureSEC source: 0001209191-20-033493 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,991 Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 19 | $288.05 | $5,472.95 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 11 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,902 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F13 · price: Open market sales reported on this line occurred at a weighted average price of $288.05 (range $287.70 to $288.47). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 15 | $287.19 | $4,307.85 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 10 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,921 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $287.19 (range $286.61 to $287.60). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 10 | $286.12 | $2,861.20 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 9 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,936 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $286.12 (range $285.60 to $286.43). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 5 | $284.98 | $1,424.90 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 8 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,946 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $284.98 (range $284.56 to $285.43). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 3 | $283.74 | $851.22 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 7 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,951 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $283.74 (range $283.44 to $284.05). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 6 | $282.77 | $1,696.62 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,954 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $282.77 (range $282.36 to $283.28). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 4 | $281.55 | $1,126.20 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,960 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $281.55 (range $281.24 to $282.20). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 9 | $280.47 | $2,524.23 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,964 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $280.47 (range $280.21 to $280.68). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 5 | $279.48 | $1,397.40 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,973 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $279.48 (range $278.84 to $279.82). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 4 | $276.44 | $1,105.76 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,978 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $276.44 (range $276.23 to $276.75). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:21 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2 | $274.98 | $549.96 |
DisclosureSEC source: 0001209191-20-030464 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,982 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $274.98 (range $274.67 to $275.28). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 9 | $288.23 | $2,594.07 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 12 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $288.23 (range $287.96 to $288.47). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 18 | $287.50 | $5,175.00 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 11 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,847 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $287.50 (range $286.96 to $287.88). Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:28 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 9 | $286.27 | $2,576.43 |
DisclosureSEC source: 0001209191-20-030479 · doc4.xml · nonDerivative · entry 10 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,865 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $286.27 (range $285.70 to $286.68). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.